Takeda Pharmaceutical Company
TAKNYSEUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $20.93 Prior regular-session close from the quote source.
- $20.68–$20.86 Regular-session low and high so far today.
- 2.0M Regular-session shares traded · Nov 11, 4:00 PM ET.
- Not yet confirmed The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
- $13.91–$21.73 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own TAK if revenue growth and operating-income margins keep recovering while one-off charges, LOE and acquisition amortization don’t reappear.
TAK price history
Loading recent earnings…
Investment thesis
What must happen next
Takeda’s global specialty portfolio will continue to produce positive top-line growth, sustaining operating cash generation that funds R&D, M&A and debt paydown.HoldingMateriality: High
Revenue increased from ¥3,569,006,000,000 (FY2022) to ¥4,581,551,000,000 (FY2025), showing multi-year top-line growth. If revenue growth persists, the company can deleverage and reinvest without sacrificing cash returns; if it doesn’t, cash flow and strategic optionality shrink.
Watch: Loss of exclusivity or swift uptake of generic/biosimilar competition against one or more of Takeda’s top-selling products (market-level drug LOE).
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Revenue increased from ¥3,569,006,000,000 (FY2022) to ¥4,581,551,000,000 (FY2025), showing multi-year top-line growth.
Open source ↗Sustained margin recovery depends on the absence of repeat restructuring, impairment, or large acquisition-related amortization charges; operating_income must grow with revenue rather than being driven by one-offs.HoldingMateriality: High
Operating income fell from ¥490,505,000,000 (FY2023) to ¥214,075,000,000 (FY2024) then recovered to ¥342,586,000,000 (FY2025), showing volatility tied to non‑recurring items. If operating_income grows proportionally with revenue, operating margins and earnings will recover; recurring large non-cash charges would keep reported profits and ROIC depressed despite healthy sales.
Watch: New large acquisition bringing significant purchase accounting amortization/impairment or repeated restructuring charges that depress operating results.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Operating income fell from ¥490,505,000,000 (FY2023) to ¥214,075,000,000 (FY2024) then recovered to ¥342,586,000,000 (FY2025), showing volatility tied to non‑recurring items.
Open source ↗Operating cash flow at ~¥1.0T enables meaningful deleveraging and strategic investment if maintained, because cash generation exceeds typical capex/R&D needs and can be allocated to reduce liabilities.StrengtheningMateriality: Medium
Operating_cash_flow recovered from ¥716,344,000,000 (FY2024) to ¥1,057,182,000,000 (FY2025). Consistent ¥1T-level OCF funds debt paydown and optionality (buybacks, deals, R&D) without needing dilutive equity or heavy new debt.
Watch: Large cash outflows not related to operations (big acquisition payments, large litigation settlements, or major special dividends) that consume OCF.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Operating_cash_flow recovered from ¥716,344,000,000 (FY2024) to ¥1,057,182,000,000 (FY2025).
Open source ↗Absent durable net income improvement or aggressive buybacks, EPS will remain depressed because diluted earnings have fallen sharply and require either higher net_income or lower share count to recover.StrengtheningMateriality: Medium
EPS diluted declined from ¥201.94 (FY2023) to ¥67.23 (FY2025), indicating large pressure on per-share earnings. EPS drives equity returns; persistent low EPS keeps valuation anchored low even if revenue grows.
Watch: Management launches a sizable and sustained share‑repurchase program materially reducing share count.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
EPS diluted declined from ¥201.94 (FY2023) to ¥67.23 (FY2025), indicating large pressure on per-share earnings.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Takeda’s global specialty portfolio will continue to produce positive top-line growth, sustaining operating cash generation that funds R&D, M&A and debt paydown. If revenue growth persists, the company can deleverage and reinvest without sacrificing cash returns; if it doesn’t, cash flow and strategic optionality shrink.
Sustained margin recovery depends on the absence of repeat restructuring, impairment, or large acquisition-related amortization charges; operating_income must grow with revenue rather than being driven by one-offs. If operating_income grows proportionally with revenue, operating margins and earnings will recover; recurring large non-cash charges would keep reported profits and ROIC depressed despite healthy sales.
Operating cash flow at ~¥1.0T enables meaningful deleveraging and strategic investment if maintained, because cash generation exceeds typical capex/R&D needs and can be allocated to reduce liabilities. Consistent ¥1T-level OCF funds debt paydown and optionality (buybacks, deals, R&D) without needing dilutive equity or heavy new debt.
Absent durable net income improvement or aggressive buybacks, EPS will remain depressed because diluted earnings have fallen sharply and require either higher net_income or lower share count to recover. EPS drives equity returns; persistent low EPS keeps valuation anchored low even if revenue grows.
All standing thesis claims
Original report summary
revenue growth and operating-income margins keep recovering while one-off charges, LOE and acquisition amortization don’t reappear.
Bull case and bear case
Bull case and bear case for Takeda Pharmaceutical Co
Where the evidence on Takeda Pharmaceutical Co stands: Holding on the latest evidence (Nov 6, 2026). Of its 4 thesis points, 2 strengthening and 2 holding.
Bull case: what the evidence supports
Takeda’s global specialty portfolio will continue to produce positive top-line growth, sustaining operating cash generation that funds R&D, M&A and debt paydown.
Sustained margin recovery depends on the absence of repeat restructuring, impairment, or large acquisition-related amortization charges; operating_income must grow with revenue rather than being driven by one-offs.
Operating cash flow at ~¥1.0T enables meaningful deleveraging and strategic investment if maintained, because cash generation exceeds typical capex/R&D needs and can be allocated to reduce liabilities.
Absent durable net income improvement or aggressive buybacks, EPS will remain depressed because diluted earnings have fallen sharply and require either higher net_income or lower share count to recover.
Bear case: what would count against it
Loss of exclusivity or swift uptake of generic/biosimilar competition against one or more of Takeda’s top-selling products (market-level drug LOE).
New large acquisition bringing significant purchase accounting amortization/impairment or repeated restructuring charges that depress operating results.
Large cash outflows not related to operations (big acquisition payments, large litigation settlements, or major special dividends) that consume OCF.
Thesis-Break Engine
What has broken in Takeda Pharmaceutical Co’s thesis
Each break OptimistFi flagged on Takeda Pharmaceutical Co, dated — with what has historically followed the same kind of break across the market, not a forecast for Takeda Pharmaceutical Co.
- Revenue decline
Across all companies, this kind of break has happened 8,727 times before. Those stocks trailed comparable companies by a median of 1% over the next six months, and 37% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedForeign issuer material report (6-K).
Takeda Pharmaceutical Co filed an SEC report on 2026-10-29: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.
- MixedForeign issuer material report (6-K).
Takeda Pharmaceutical Co filed an SEC report on 2026-09-14: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.
- MixedForeign issuer material report (6-K).
Takeda Pharmaceutical Co filed an SEC report on 2026-08-31: Foreign issuer material report (6-K). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Loss of exclusivity or swift uptake of generic/biosimilar competition against one or more of Takeda’s top-selling products (market-level drug LOE).
- New large acquisition bringing significant purchase accounting amortization/impairment or repeated restructuring charges that depress operating results.
- Large cash outflows not related to operations (big acquisition payments, large litigation settlements, or major special dividends) that consume OCF.
- Management launches a sizable and sustained share‑repurchase program materially reducing share count.
TAK news
Loading headlines…
Financial statements
TAK income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
TAK: quick answers
- What is TAK's short interest?
- As of October 30, 2026, 3.1M TAK shares were sold short, down 6.8% from the count before. At the stock's average daily volume that is 1.0 days to cover. FINRA publishes the count twice a month. TAK short interest history
- Have members of Congress traded TAK?
- 8 trades in TAK have been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed TAK trade